The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.

abstract：:DNA vaccination consists of administering an antigen-coding nucleotide sequence. In order to improve the efficacy of DNA vaccines, electroporation is one of the most commonly used methods to enhance DNA uptake. Here, we discuss additional immunological effects of electroporation that are key aspects for inducing immun...

journal_title：Oncoimmunology

authors： Calvet CY,André FM,Mir LM

更新日期：2014-04-29 00:00:00

abstract：:A cancer-promoting role of fibrogenesis in the liver has long been speculated; however, the molecular mechanisms regarding this phenomenon are largely unknown. We demonstrated in our previous study that macrophage-derived S100A4 promotes liver fibrosis via activation of hepatic stellate cells; however, whether and how...

journal_title：Oncoimmunology

authors： Li Y,Wang J,Song K,Liu S,Zhang H,Wang F,Ni C,Zhai W,Liang J,Qin Z,Zhang J

更新日期：2020-02-14 00:00:00

abstract：:Programmed death ligand 1 (PD-L1) expression represents a mechanism of immune escape by inhibiting T cell immunity. This study systematically evaluated the expression of PD-L1, spatial distribution of CD3+ immune cells and the relationship of both factors to survival in nasopharyngeal carcinoma (NPC) patients. A total...

journal_title：Oncoimmunology

authors： Zhu Q,Cai MY,Chen CL,Hu H,Lin HX,Li M,Weng DS,Zhao JJ,Guo L,Xia JC

更新日期：2017-04-27 00:00:00

abstract：:Immunotherapy with oncolytic herpes simplex virus-1 therapy offers an innovative, targeted, less-toxic approach for treating brain tumors. However, a major obstacle in maximizing oncolytic virotherapy is a lack of comprehensive understanding of the underlying mechanisms that unfold in CNS tumors/associated microenviro...

journal_title：Oncoimmunology

authors： Bernstock JD,Vicario N,Rong L,Valdes PA,Choi BD,Chen JA,DiToro D,Osorio DS,Kachurak K,Gessler F,Johnston JM Jr,Atkinson TP,Whitley RJ,Bag AK,Gillespie GY,Markert JM,Maric D,Friedman GK

更新日期：2019-10-21 00:00:00

abstract：:The intestinal microbiota plays a key role in the pathogenesis of acute graft-versus-host disease (aGVHD). High-dose conditioning regimens given prior to allogeneic hematopoietic stem cell transplantation (aHSCT) modulate the composition of gut microbiota and damage the gut epithelial barrier, resulting in increased s...

journal_title：Oncoimmunology

authors： Routy B,Letendre C,Enot D,Chénard-Poirier M,Mehraj V,Séguin NC,Guenda K,Gagnon K,Woerther PL,Ghez D,Lachance S

更新日期：2016-12-27 00:00:00

abstract：:Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(+) DCs, upregulated...

journal_title：Oncoimmunology

authors： Natarajan G,Oghumu S,Terrazas C,Varikuti S,Byrd JC,Satoskar AR

更新日期：2016-03-10 00:00:00

abstract：:The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictiv...

journal_title：Oncoimmunology

authors： Lanzi A,Sinicrope FA,Benson AB,Galon J

更新日期：2020-07-20 00:00:00

abstract：:The immune microenvironment in follicular lymphoma (FL) plays an important role in controlling disease characteristics. To characterize the T-cell receptor (TCR) repertoire in follicular lymphoma (FL) tissues, we applied a next-generation sequencing platform and deeply sequenced TCR cDNAs of T-cell subset populations ...

journal_title：Oncoimmunology

authors： Liu X,Venkataraman G,Lin J,Kiyotani K,Smith S,Montoya M,Nakamura Y,Kline J

更新日期：2015-02-03 00:00:00

abstract：:Agonistic tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor-specific antibodies are attractive antitumor therapeutics. Recently, our group has generated several human monoclonal antibodies (mAbs) to TRAIL-receptor-1 (TRAIL-R1) (TR1-IgGs) using ISAAC technology. However, these TR1-IgGs did ...

journal_title：Oncoimmunology

authors： Piao X,Ozawa T,Hamana H,Shitaoka K,Jin A,Kishi H,Muraguchi A

更新日期：2016-05-04 00:00:00

abstract：:Cytokine-Induced Killer (CIK) cells share several functional and phenotypical properties of both T and natural killer (NK) cells. They represent an attractive approach for cell-based immunotherapy, as they do not require antigen-specific priming for tumor cell recognition, and can be rapidly expanded in vitro. Their r...

journal_title：Oncoimmunology

authors： Sommaggio R,Cappuzzello E,Dalla Pietà A,Tosi A,Palmerini P,Carpanese D,Nicolè L,Rosato A

更新日期：2020-06-11 00:00:00

abstract：:Immune tolerance induced by regulatory mechanisms is an integral and fundamental part of immunity. In therapeutic settings, however, tolerance may significantly limit efficacy. Here, we summarize possible strategies to enhance therapeutic antibody dependent cellular cytotoxicity by overcoming NK cell tolerance. ...

journal_title：Oncoimmunology

authors： Terszowski G,Klein C,Schmied L,Stern M

更新日期：2015-04-02 00:00:00

abstract：:Despite recent therapeutic progress, plasmablastic lymphoma (PBL), a distinct entity of high grade B cell lymphoma, is still an aggressive lymphoma with adverse prognosis. PBL commonly occurs in patients with HIV infection and PBL cells frequently express Epstein Barr virus (EBV) genome with type I latency. Occasional...

journal_title：Oncoimmunology

authors： Gravelle P,Péricart S,Tosolini M,Fabiani B,Coppo P,Amara N,Traverse-Gléhen A,Van Acker N,Brousset P,Fournie JJ,Laurent C

更新日期：2018-07-30 00:00:00

abstract：:The recent approval of clincially effective immune checkpoint inhibitors illustrates the potential of cancer immunotherapy. A challenging task remains the identification of specific targets guiding immunotherapy. Facilitated by technical advances, the direct identification of physiologically relevant targets is enable...

journal_title：Oncoimmunology

authors： Peper JK,Bösmüller HC,Schuster H,Gückel B,Hörzer H,Roehle K,Schäfer R,Wagner P,Rammensee HG,Stevanović S,Fend F,Staebler A

更新日期：2015-07-01 00:00:00

abstract：:A number of studies point to an aberrant differentiation and accumulation of CD14+ PD-L1+ M2-macrophage-like cells in the microenvironment of cervical cancer, which promote immunosuppressive conditions and are associated with tumor invasion, angiogenesis and metastasis. Therapeutic targeting of these macrophages may t...

journal_title：Oncoimmunology

authors： Heeren AM,Kenter GG,Jordanova ES,de Gruijl TD

更新日期：2015-05-07 00:00:00

abstract：:Oncolytic virotherapy is emerging as a promising approach for the treatment of several neoplasms. The term "oncolytic viruses" is generally employed to indicate naturally occurring or genetically engineered attenuated viral particles that cause the demise of malignant cells while sparing their non-transformed counterp...

journal_title：Oncoimmunology

authors： Vacchelli E,Eggermont A,Sautès-Fridman C,Galon J,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2013-06-01 00:00:00

abstract：:Although the proteasome inhibitor bortezomib has significantly improved the survival of patients with multiple myeloma (MM), the disease remains fatal as most patients eventually develop progressive disease. Recent data indicate that MM cells can evade bortezomib-induced cell death by undergoing autophagy as a consequ...

journal_title：Oncoimmunology

authors： Carlsten M,Namazi A,Reger R,Levy E,Berg M,St Hilaire C,Childs RW

更新日期：2018-11-02 00:00:00

abstract：:The efficacy of antitumoral responses can be increased using combinatorial vaccine strategies. We recently showed that vaccination could be optimized by local administration of diverse molecular or bacterial agents to target and augment antitumoral CD8 T cells in the genital mucosa (GM) and increase regression of cerv...

journal_title：Oncoimmunology

authors： Domingos-Pereira S,Hojeij R,Reggi E,Derré L,Chevalier MF,Romero P,Jichlinski P,Nardelli-Haefliger D

更新日期：2015-05-22 00:00:00

abstract：BACKGROUND:Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. METHODS:Retrospective analysis of 48 stage IV melanoma ...

journal_title：Oncoimmunology

authors： Boudewijns S,Koornstra RH,Westdorp H,Schreibelt G,van den Eertwegh AJ,Geukes Foppen MH,Haanen JB,de Vries IJ,Figdor CG,Bol KF,Gerritsen WR

更新日期：2016-06-17 00:00:00

abstract：:Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and t...

journal_title：Oncoimmunology

authors： Steinbach A,Winter J,Reuschenbach M,Blatnik R,Klevenz A,Bertrand M,Hoppe S,von Knebel Doeberitz M,Grabowska AK,Riemer AB

更新日期：2017-06-20 00:00:00

abstract：:A major advantage of immunotherapy of cancer is that effector cells induced at one site should be able to kill metastatic cancer cells in other sites or tissues. However, different tissues have unique immune components, and very little is known about whether effector T cells induced against tumors in one tissue can wo...

journal_title：Oncoimmunology

authors： O'Konek JJ,Ambrosino E,Bloom AC,Pasquet L,Massilamany C,Xia Z,Terabe M,Berzofsky JA

更新日期：2018-04-09 00:00:00

abstract：:Despite the clinical success of anti-PD1 antibody (α-PD1) therapy, the immune mechanisms contributing to the antineoplastic response remain unclear. Here, we describe novel aspects of the immune response involved in α-PD1-induced antitumor effects using an orthotopic Kras (G12D)/p53(R172H)/Pdx1-Cre (KPC) model of panc...

journal_title：Oncoimmunology

authors： D'Alincourt Salazar M,Manuel ER,Tsai W,D'Apuzzo M,Goldstein L,Blazar BR,Diamond DJ

更新日期：2016-03-16 00:00:00

abstract：:Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (...

journal_title：Oncoimmunology

authors： Deng WW,Mao L,Yu GT,Bu LL,Ma SR,Liu B,Gutkind JS,Kulkarni AB,Zhang WF,Sun ZJ

更新日期：2016-10-07 00:00:00

abstract：:Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. Planned tumor biopsy...

journal_title：Oncoimmunology

authors： Du S,McCall N,Park K,Guan Q,Fontina P,Ertel A,Zhan T,Dicker AP,Lu B

更新日期：2018-01-29 00:00:00

abstract：:Checkpoint inhibition has established immunotherapy as a major modality of cancer treatment. However, the success of cancer immunotherapy is still limited as immune regulation of tumor immunity is very complicated and mechanisms involved may also differ among cancer types. Beside checkpoints, other good candidates for...

journal_title：Oncoimmunology

authors： Terabe M,Robertson FC,Clark K,De Ravin E,Bloom A,Venzon DJ,Kato S,Mirza A,Berzofsky JA

更新日期：2017-03-31 00:00:00

abstract：:Although the profile of safety of tumor-targeted oncolytic virus (TOV) is encouraging, the antitumor efficacy of TOV alone is disappointing. Interleukin-10 (IL-10) plays an important role in carcinogenesis and anti-virus immunity. Here we report that tumor-targeted oncolytic vaccinia virus (VV) armed with IL10 shows p...

journal_title：Oncoimmunology

authors： Chard LS,Lemoine NR,Wang Y

更新日期：2015-07-20 00:00:00

abstract：:Estrogen receptors have recently been demonstrated at the cell surface. Unlike nuclear receptors, they are able to trigger rapid responses inside the cells. In this study, we evaluated the presence and the possible role of autoantibodies specific to estrogen receptor (anti-ER Abs) in the peripheral blood of breast can...

journal_title：Oncoimmunology

authors： Maselli A,Capoccia S,Pugliese P,Raggi C,Cirulli F,Fabi A,Malorni W,Pierdominici M,Ortona E

更新日期：2015-08-12 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is a neoplasm of myeloid origin characterized by a clonal proliferation of CD1a(+)/CD207(+) dendritic cells. Recurrent BRAF V600E mutation has been reported in LCH. In the present report, we confirm the feasibility of the high-specificity monoclonal antibody VE1 for detecting BRAF V...

journal_title：Oncoimmunology

authors： Zeng K,Wang Z,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Y,Yu Z,Yan Q,Guo S,Wei J,Guo Y

更新日期：2016-06-14 00:00:00

abstract：:We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadju...

journal_title：Oncoimmunology

authors： Kim SW,Goedegebuure P,Gillanders WE

更新日期：2016-02-26 00:00:00

abstract：:The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced...

journal_title：Oncoimmunology

authors： Ding ZC,Liu C,Cao Y,Habtetsion T,Kuczma M,Pi W,Kong H,Cacan E,Greer SF,Cui Y,Blazar BR,Munn DH,Zhou G

更新日期：2016-04-25 00:00:00

abstract：:Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-...

journal_title：Oncoimmunology

authors： Dhodapkar MV,Dhodapkar KM

更新日期：2014-08-03 00:00:00